Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

S. Buti, M. Bersanelli, F. Perrone, M. Tiseo, M. Tucci, V. Adamo, L.S. Stucci, A. Russo, E.T. Tanda, F. Spagnolo, F. Rastelli, F. Pergolesi, D. Santini, M. Russano, C. Anesi, R. Giusti, M. Filetti, P. Marchetti, A. Botticelli, A. GelibterM.A. Occhipinti, M. Ferrari, M.G. Vitale, L. Nicolardi, R. Chiari, E. Rijavec, O. Nigro, A. Tuzi, M. De Tursi, P. Di Marino, F. Conforti, P. Queirolo, S. Bracarda, S. Macrini, S. Gori, F. Zoratto, E. Veltri, B. Di Cocco, D. Mallardo, M. Santoni, L. Patruno, G. Porzio, C. Ficorella, D.J. Pinato, P.A. Ascierto, A. Cortellini

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)18-28
Number of pages11
JournalEuropean Journal of Cancer
Volume142
DOIs
Publication statusPublished - 2021

Keywords

  • Antibiotics
  • Cancer patients
  • Concomitant medications
  • Corticosteroids
  • Drugs
  • Immune checkpoint inhibitors
  • Immunotherapy
  • Index
  • Prognostic
  • Proton-pump inhibitors
  • Score
  • acetylsalicylic acid
  • antibiotic agent
  • corticosteroid
  • dipeptidyl carboxypeptidase inhibitor
  • hydroxymethylglutaryl coenzyme A reductase inhibitor
  • immune checkpoint inhibitor
  • metformin
  • prednisone
  • programmed death 1 ligand 1
  • proton pump inhibitor
  • advanced cancer
  • aged
  • Article
  • body mass
  • cancer immunotherapy
  • cancer prognosis
  • cancer staging
  • clinical outcome
  • clinical practice
  • cohort analysis
  • controlled study
  • disease burden
  • disease exacerbation
  • female
  • follow up
  • human
  • major clinical study
  • male
  • melanoma
  • multicenter study
  • neutrophil lymphocyte ratio
  • non small cell lung cancer
  • nonhuman
  • overall survival
  • priority journal
  • prognostic assessment
  • progression free survival
  • renal cell carcinoma
  • treatment response
  • treatment response time
  • adult
  • immunotherapy
  • lung tumor
  • middle aged
  • procedures
  • prognosis
  • reproducibility
  • treatment outcome
  • very elderly
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Non-Small-Cell Lung
  • Female
  • Humans
  • Immune Checkpoint Inhibitors
  • Lung Neoplasms
  • Male
  • Middle Aged
  • Prognosis
  • Reproducibility of Results
  • Treatment Outcome

Cite this